ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

ACELYRIN announced positive Phase 1/2 trial results for lonigutamab, a subcutaneous anti-IGF-1R treatment for Thyroid Eye Disease (TED), showing rapid improvements in proptosis and clinical activity score within 3 weeks. The treatment, well-tolerated with no serious adverse events, demonstrated potential for longer-term dosing to enhance clinical response depth and durability. A Phase 2b/3 trial is planned for 2024.